Professional-grade financial intelligence

20M+ securities. Real-time data. Institutional insights.

Subscribe for $2

Trusted by professionals at Goldman Sachs, BlackRock, and JPMorgan

Overview
Profile
Nxera Pharma Co Stock

Nxera Pharma Co Stock 4565.T

4565.T
JP3431300007
A0B7EK

Price

936.00
Today +/-
+0.24
Today %
+4.59 %

Nxera Pharma Co stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Nxera Pharma Co stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Nxera Pharma Co stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Nxera Pharma Co stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Nxera Pharma Co's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Nxera Pharma Co Stock Price History

DateNxera Pharma Co Price
8/13/2025936.00 undefined
8/12/2025894.00 undefined
8/8/2025883.00 undefined
8/7/2025890.00 undefined
8/6/2025880.00 undefined
8/5/2025942.00 undefined
8/4/2025921.00 undefined
8/1/2025923.00 undefined
7/31/2025920.00 undefined
7/30/2025907.00 undefined
7/29/2025867.00 undefined
7/28/2025876.00 undefined
7/25/2025877.00 undefined
7/24/2025881.00 undefined
7/23/2025863.00 undefined
7/22/2025840.00 undefined
7/18/2025857.00 undefined
7/17/2025868.00 undefined
7/16/2025863.00 undefined
7/15/2025871.00 undefined

Nxera Pharma Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Nxera Pharma Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Nxera Pharma Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Nxera Pharma Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Nxera Pharma Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Nxera Pharma Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Nxera Pharma Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Nxera Pharma Co’s growth potential.

Nxera Pharma Co Revenue, EBIT and net profit per share

DateNxera Pharma Co RevenueNxera Pharma Co EBITNxera Pharma Co Net Income
2027e39.77 B undefined0 undefined2.8 B undefined
2026e39.47 B undefined0 undefined4.38 B undefined
2025e36.56 B undefined0 undefined741 M undefined
202428.84 B undefined-6.69 B undefined-4.84 B undefined
202312.77 B undefined-10.46 B undefined-7.19 B undefined
202215.57 B undefined2.81 B undefined382 M undefined
202117.71 B undefined6.91 B undefined1.02 B undefined
20208.84 B undefined854 M undefined1.48 B undefined
20199.73 B undefined960 M undefined1.43 B undefined
20182.87 B undefined-5.54 B undefined-5.98 B undefined
20176.96 B undefined-2.46 B undefined-2.65 B undefined
201618.9 B undefined12.13 B undefined9.31 B undefined
20158.15 B undefined930 M undefined-1.43 B undefined
20143.67 B undefined1.03 B undefined516 M undefined
20132.07 B undefined682 M undefined1.53 B undefined
20121.96 B undefined-953 M undefined-647 M undefined
2011862 M undefined-1.96 B undefined-1.95 B undefined
2010717 M undefined-1.88 B undefined-1.87 B undefined
2009920 M undefined-1.86 B undefined-1.77 B undefined
2008153 M undefined-3.67 B undefined-3.94 B undefined
2007709 M undefined-6.27 B undefined-6.5 B undefined
2006740 M undefined-6.65 B undefined-6.24 B undefined
2005416 M undefined-4.41 B undefined-4.18 B undefined

Nxera Pharma Co Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (B)
NET INCOME (B)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e
0.040.230.240.420.740.710.150.920.720.861.962.073.678.1518.96.962.879.738.8417.7115.5712.7728.8436.5639.4739.77
-415.917.4970.4977.88-4.19-78.42501.31-22.0720.22127.265.6777.34122.04131.89-63.20-58.71238.65-9.09100.32-12.10-18.00125.8726.807.940.77
61.3694.7194.6712.2633.6582.7920.2686.0992.8970.5383.3687.83578.0299.95112.26305.0988.3491.2591.3994.7394.0575.7073.5958.0353.7653.35
0.030.220.230.050.250.590.030.790.670.611.631.8208.15002.548.888.0816.7814.649.6621.22000
-0.71-0.91-1.82-4.18-6.24-6.5-3.94-1.77-1.87-1.95-0.651.530.52-1.439.31-2.65-5.981.431.481.020.38-7.19-4.840.744.382.8
-28.0599.34129.4549.434.23-39.44-55.095.824.38-66.89-335.86-66.19-377.52-750.21-128.50125.21-123.963.28-31.24-62.44-1,982.98-32.74-115.30491.89-36.03
25252333404747474747474955.5961.2167.8170.6976.2677.4879.4981.1982.5982.5289.73000
--------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Nxera Pharma Co Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Nxera Pharma Co is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (B)
RECEIVABLES (B)
OTHER REC. (B)
INVENTORIES (B)
OTHER CURRENT LIAB. (B)
CURRENT ASSETS (B)
TANGIBLE ASSETS (B)
LONG-T. INVEST. (B)
LONG-T. REC. (M)
INTANGIBLE ASSETS (B)
GOODWILL (B)
OTHER NON-CURRENT ASSETS (B)
NON-CURRENT ASSETS (B)
TOTAL ASSETS (B)
LIABILITIES
COMMON STOCK (B)
ADDITIONAL PAID-IN CAPITAL (B)
RETAINED EARNINGS (M)
OTHER EQUITY (B)
UNREAL. GAINS/LOSSES (M)
EQUITY (B)
LIABILITIES (B)
PROVISIONS (B)
OTHER SHORT-TERM LIAB. (B)
SHORT-TERM DEBTS (B)
LONG-TERM DEBT PORTION (B)
SHORT-TERM REC. (B)
LONG-T. LIAB. (B)
DEFERRED TAXES (B)
OTHER LIAB. (B)
LONG-T. LIABILITIES (B)
DEBT (B)
TOTAL CAPITAL (B)
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
                                             
0.2719.79.468.964.911.771.861.751.52.547.225.5710.0713.928.2818.7615.3840.0160.1766.5649.3836.2
000.010.150.090.07-0.060.0400.030.040.12.480.11.380.750.991.920.942.142.465.066.7
0.04000000000000.58001.062.061.770.420.070.062.12.39
000000000.060000000000002.98.84
00.040.050.460.490.490.340.080.060.080.030.150.390.470.540.830.480.50.650.430.875.673.73
0.321.049.7610.079.545.472.051.981.871.612.627.479.0210.6415.8230.9222.2819.5642.0262.8169.9465.1157.86
0.020.030.030.050.140.110.050.040.050.060.060.060.270.270.421.162.724.123.823.823.797.97.47
0.030.030.050.090.020000000000.616.045.165.594.686.041.743.274.52
0000000000000000000014000
000.010.010.010.010.010.010.010.260.250.7221.7119.3116.9716.6714.371311.89.128.5852.2951.91
00015.0413.4411.7810.198.67.015.433.845.4316.4315.4314.1514.6914.1814.3714.1315.115.3124.6225.69
0.020.040.030.050.050.040.080.040.040.040.040.910.411.710.120.020.290.040.010.10.064.014.05
0.070.090.1215.2413.6611.9310.328.77.125.784.187.1238.8136.7232.2738.5736.737.1234.4534.1829.6292.0993.64
0.391.139.8825.3123.217.412.3710.678.997.396.814.5847.8347.3548.0969.4958.9956.6876.4796.9999.56157.2151.5
                                             
0.861.665.8715.2316.9316.9716.9716.9716.9916.9917.0619.4519.4825.962636.7836.8537.4840.2241.0441.3446.8147.17
0.851.657.9217.2418.9519.1319.0419.0619.1419.2119.2221.577.7714.2614.6325.6126.0426.5530.4529.129.5334.0535.07
-1,345-2,249-4,069-8,245-14,544-21,048-24,987-26,756-28,628-30,582-31,229-26,934-12,614-14,184-4,873-7,527-13,696-12,264-10,785-9,768-8,911-16,104-20,942
0000.260.760.741.121.11.161.181.280.260-2.89-7.4100-6.77-7.57-3.72-3.431.986.33
010000000100000-5,982-7,6238459819-58484891
0.361.069.7324.4822.115.7812.1410.388.666.86.3314.3614.6423.1428.3648.8841.5845.0852.3857.4757.9466.8168.52
0000.020.060.0600.060.060.060.160.040000000004.364.11
000001.110.180.190.20.160.030.050.10.140.120.190.150.740.760.850.881.081.52
0.030.070.150.811.040.460.050.050.070.070.10.121.291.333.52.412.311.392.066.153.049.227.36
00000000000019.880000000000
00000000000001.991.9932.990.180.170.190.186.776.69
0.030.070.150.831.11.620.230.30.340.290.280.2121.273.465.615.65.452.32.997.194.0921.4319.68
00000000000006.854.916.183.973.1916.4529.0829.5667.261.21
0000000000004.463.693.183.082.542.012.462.712.921.491.86
000000000000.027.0710.096.035.755.454.12.190.544.914.514.28
000000000000.0211.5220.6314.1215.0111.969.321.132.3337.3973.267.35
0.030.070.150.831.11.620.230.30.340.290.280.2332.7924.0919.7320.617.4111.624.0839.5241.4894.6387.03
0.391.139.8825.3123.217.4112.3710.678.997.096.6114.5847.4347.2348.0869.4858.9856.6876.4796.9999.42161.44155.55
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Nxera Pharma Co provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Nxera Pharma Co's financial health and stability.

Assets

Nxera Pharma Co's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Nxera Pharma Co must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Nxera Pharma Co after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Nxera Pharma Co's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)
DEPRECIATION (B)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (B)
NON-CASH ITEM (B)
PAID INTEREST (M)
PAID TAXES (B)
NET CASH FLOW FROM OPERATING ACTIVITIES (B)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (B)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (B)
NET CHANGE IN EQUITY (B)
CASH FLOW FROM FINANCING ACTIVITIES (B)
CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (B)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
2002200320042005200620072008200920102011201220132014201520162017null201820192020202120222023
-0.71-0.91-1.82-4.32-6.52-6.78-4.04-1.77-1.87-1.95-0.760.741.3-3.312.48-3.7-3.7-7.240.531.620.431.08-10.68
0.010.010.010.961.631.651.621.61.611.611.610.020.10.930.921.031.030.881.491.351.281.352.48
00000000000000000000000
-0.030.040.070.110.640.48-1.020.310.12-0.040.07-0.16-1.442.38-0.82-1.23-1.230.2712.67-1.333.961.09
00.010.040.060.070.710.45-0.110.060.09-0.1-0.230.144.470.271.741.742.10.42-0.976.713.571.84
00000000000003111291621629910360157171241
0000-0.02-0.29-0.05-0.18-0.0400.010.010.02-0.44-02.232.230-0.79-1.17-0.090.261.39
-0.74-0.86-1.7-3.19-4.18-3.95-2.990.03-0.09-0.290.830.360.094.4712.85-2.17-2.17-43.444.677.19.95-5.27
-6-15-25-17-117-62-1-15-7-275-28-11-88-130-332-880-880-2,159-280-105-201-303-851
-0.04-0.03-0.022.62-0.12-0.05-0.040.02-0.03-0.28-0.03-0.32-22.02-0.34-2.33-6.15-6.15-2.81-0.25-0.150.281.04-63.79
-0.03-0.0102.64-00.02-0.040.04-0.02-00-0.31-21.93-0.21-2-5.27-5.27-0.650.03-0.050.481.35-62.94
00000000000000000000000
00000000000019.848.8-22.142.14-2.26-7.0615.7310.71-0.2138.37
0.171.610.430.053.360.05000.0200.094.720.0312.880.0621.1721.170.080.755.150.609.98
0.171.610.430.053.360.04000.020.30.094.3819.860.86-6.3122.6422.64-2.27-6.9620.2811.12-4.8948.33
00000-30003000-3490-20,686-4,365-666-666-97-650-597-191-4,681-27
0000000000000-135000000000
-0.60.728.7-0.24-0.5-4.05-3.140.09-0.11-0.251.044.68-1.644.53.8314.3814.38-9.52-3.3924.6320.086.47-17.49
-741-870-1,726-3,207-4,299-4,012-2,98717-96-56280035264,34012,522-3,0470-6,1543,1614,5676,8949,649-6,124
00000000000000000000000

Nxera Pharma Co stock margins

The Nxera Pharma Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Nxera Pharma Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Nxera Pharma Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Nxera Pharma Co's sales revenue. A higher gross margin percentage indicates that the Nxera Pharma Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Nxera Pharma Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Nxera Pharma Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Nxera Pharma Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Nxera Pharma Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Nxera Pharma Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Nxera Pharma Co Margin History

Nxera Pharma Co Gross marginNxera Pharma Co Profit marginNxera Pharma Co EBIT marginNxera Pharma Co Profit margin
2027e73.59 %0 %7.05 %
2026e73.59 %0 %11.1 %
2025e73.59 %0 %2.03 %
202473.59 %-23.19 %-16.78 %
202375.7 %-81.94 %-56.34 %
202294.05 %18.06 %2.45 %
202194.73 %39.01 %5.74 %
202091.39 %9.66 %16.73 %
201991.25 %9.87 %14.72 %
201888.34 %-193 %-208.11 %
201773.59 %-35.4 %-38.16 %
201673.59 %64.16 %49.26 %
201599.95 %11.41 %-17.57 %
201473.59 %28.11 %14.06 %
201387.83 %32.95 %73.72 %
201283.36 %-48.65 %-33.03 %
201170.53 %-227.61 %-226.68 %
201092.89 %-261.65 %-261.09 %
200986.09 %-201.63 %-192.28 %
200820.26 %-2,397.39 %-2,574.51 %
200782.79 %-884.34 %-917.35 %
200633.65 %-898.78 %-843.24 %
200512.26 %-1,059.38 %-1,003.85 %

Nxera Pharma Co Stock Sales Revenue, EBIT, Earnings per Share

The Nxera Pharma Co earnings per share therefore indicates how much revenue Nxera Pharma Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Nxera Pharma Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Nxera Pharma Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Nxera Pharma Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Nxera Pharma Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Nxera Pharma Co Revenue, EBIT and net profit per share

DateNxera Pharma Co Sales per ShareNxera Pharma Co EBIT per shareNxera Pharma Co Earnings per Share
2027e443.23 undefined0 undefined31.23 undefined
2026e439.84 undefined0 undefined48.82 undefined
2025e407.48 undefined0 undefined8.26 undefined
2024321.35 undefined-74.52 undefined-53.92 undefined
2023154.71 undefined-126.77 undefined-87.17 undefined
2022188.51 undefined34.05 undefined4.63 undefined
2021218.16 undefined85.11 undefined12.53 undefined
2020111.23 undefined10.74 undefined18.61 undefined
2019125.52 undefined12.39 undefined18.48 undefined
201837.66 undefined-72.69 undefined-78.38 undefined
201798.39 undefined-34.83 undefined-37.55 undefined
2016278.73 undefined178.83 undefined137.31 undefined
2015133.16 undefined15.19 undefined-23.39 undefined
201466.03 undefined18.56 undefined9.28 undefined
201342.24 undefined13.92 undefined31.14 undefined
201241.68 undefined-20.28 undefined-13.77 undefined
201118.34 undefined-41.74 undefined-41.57 undefined
201015.26 undefined-39.91 undefined-39.83 undefined
200919.57 undefined-39.47 undefined-37.64 undefined
20083.26 undefined-78.04 undefined-83.81 undefined
200715.09 undefined-133.4 undefined-138.38 undefined
200618.5 undefined-166.28 undefined-156 undefined
200512.61 undefined-133.55 undefined-126.55 undefined

Nxera Pharma Co business model

The Sosei Group Corp. is a Japanese company that operates in the fields of pharmaceutical research and development. It was founded in 1990 as Photonamic GmbH & Co KG in Munich, Germany, before being renamed Sosei Co. Ltd. in 2003. The company is headquartered in Tokyo, Japan, and operates research and development facilities in Japan, the United Kingdom, and Denmark. Sosei is involved in several significant drug development projects and has produced some successful products in the past. Business model: The main focus of the Sosei Group Corp. is the research and development of pharmaceuticals. Its primary business model is to be involved in the entire value chain of drug development, from the discovery and characterization of new drug candidates to clinical development and regulatory approval. In order to attract partners in the pharmaceutical and biotech industry, the company offers its core competencies in drug research and development, including optimizing drug candidates and conducting clinical trials. Partnerships can be structured in the form of strategic alliances, licensing fees, milestone payments, and profit sharing. Divisions: The Sosei Group Corp. divides its activities into three main divisions: 1. Sosei Heptares: The company is a leading player in G-protein-coupled receptor (GPCR) research and development. GPCRs are a class of membrane proteins involved in regulating signal transduction processes and are of significant importance in drug development. Sosei Heptares provides its expertise and technology platform to third parties for developing new drugs targeting GPCR. 2. Sosei R&D: Sosei R&D focuses on the discovery and development of new drug candidates in various therapeutic areas, including inflammation, oncology, pain, respiratory, and mental disorders. The company utilizes its proprietary technology platform, which includes computer-aided design and synthesis optimization, to identify and develop new drugs. 3. Sosei CMC: The Sosei CMC department is responsible for developing customized processes for manufacturing pharmaceuticals. It encompasses all aspects of drug manufacturing, from formulation to manufacturing techniques. The department also works closely with other departments of the company to ensure that the drug products meet the highest quality and safety standards. Products: Sosei has developed and brought to market some successful drugs in the past. These include medications such as: 1. NVA237 (glycopyrronium bromide): An inhalation medicine for the treatment of chronic obstructive pulmonary disease (COPD). 2. QVA149 (indacaterol/glycopyrronium bromide): Another inhalation medicine approved for the treatment of COPD. 3. Sovodakso (GSK-491876): A drug candidate developed in partnership with GlaxoSmithKline (GSK) currently under investigation in phase III clinical trials for the treatment of schizophrenia. 4. Aclidinium bromide: An inhalation medicine for the treatment of COPD, developed in partnership with Almirall. In summary, the Sosei Group Corp. is a leading player in pharmaceutical research and development. The company focuses on developing novel drugs for the treatment of a variety of diseases and works closely with partners in the pharmaceutical and biotech industry. With its extensive knowledge and technological expertise, Sosei is one of the few companies capable of overcoming the challenges in drug development. Nxera Pharma Co is one of the most popular companies on Eulerpool.com.

Nxera Pharma Co SWOT Analysis

Strengths

Sosei Group Corp possesses several core strengths that contribute to its competitive advantage and market position. These strengths include a strong portfolio of innovative drug candidates, advanced drug discovery capabilities, and strategic partnerships with renowned pharmaceutical companies. These factors provide the company with a solid foundation for continued growth and success.

Weaknesses

Despite its strengths, Sosei Group Corp also faces certain weaknesses that could hinder its performance. One notable weakness is the inherent risk and regulatory challenges associated with drug development and the lengthy approval process. Additionally, the company primarily operates in the highly competitive pharmaceutical industry, which necessitates continuous investments in research and development to stay ahead of competitors.

Opportunities

Sosei Group Corp has significant opportunities for strategic growth and expansion. The increasing global demand for innovative therapeutics, particularly in areas such as oncology and neurology, presents a fertile market for the company to capitalize on. Furthermore, the growing trend of collaborations and partnerships in the pharmaceutical industry offers Sosei Group Corp the chance to leverage its expertise and forge alliances with key players, potentially unlocking new avenues for revenue generation.

Threats

Like any other business operating in the pharmaceutical sector, Sosei Group Corp faces a range of external threats that could impact its performance. These threats include intense competition from both established pharmaceutical companies and emerging biotech startups, as well as the risk of patent expirations for existing drugs. Additionally, regulatory changes or delays in the approval process may pose challenges to the company's ability to bring its innovative drug candidates to market.

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Nxera Pharma Co Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Nxera Pharma Co historical P/E ratio, EBIT multiple, and P/S ratio

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Nxera Pharma Co shares outstanding

The number of shares was Nxera Pharma Co in 2024 — This indicates how many shares 89.732 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Nxera Pharma Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Nxera Pharma Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Nxera Pharma Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Nxera Pharma Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Nxera Pharma Co stock splits

In Nxera Pharma Co's history, there have been no stock splits.

Nxera Pharma Co dividend history and estimates

In 2024, Nxera Pharma Co paid a dividend amounting to 0 undefined. Dividend means that Nxera Pharma Co distributes a portion of its profits to its owners.

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Nxera Pharma Co provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Nxera Pharma Co’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Nxera Pharma Co's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Nxera Pharma Co Dividend History

DateNxera Pharma Co Dividend
Nxera Pharma Co does not pay out any dividends.

Nxera Pharma Co dividend payout ratio

In 2024, Nxera Pharma Co had a payout ratio of 0%. The payout ratio indicates the percentage of the company's profits that Nxera Pharma Co distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Nxera Pharma Co represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Nxera Pharma Co could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Nxera Pharma Co's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Nxera Pharma Co Payout Ratio History

DateNxera Pharma Co Payout ratio
2027e0 %
2026e0 %
2025e0 %
20240 %
20230 %
20220 %
20210 %
20200 %
20190 %
20180 %
20170 %
20160 %
2015-10.69 %
20140 %
20130 %
20120 %
20110 %
20100 %
20090 %
20080 %
20070 %
20060 %
20050 %
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Nxera Pharma Co.

Nxera Pharma Co latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/202518.01 -26.37  (-246.42 %)2025 Q2
3/31/2025-40.52 -8.45  (79.15 %)2025 Q1
12/31/202466.47 -14.86  (-122.36 %)2024 Q4
9/30/2024-41.42 13.45  (132.47 %)2024 Q3
6/30/20241.98 -15.83  (-898.04 %)2024 Q2
3/31/202436.11 -36.68  (-201.59 %)2024 Q1
12/31/20238.53 -2.13  (-124.96 %)2023 Q4
9/30/202330.98 -59.92  (-293.44 %)2023 Q3
1

Eulerpool ESG Scorecard© for the Nxera Pharma Co stock

Eulerpool World ESG Rating (EESG©)

53/ 100

🌱 Environment

40

👫 Social

38

🏛️ Governance

80

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
800.66
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees46
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Nxera Pharma Co shareholders

%
Name
Stocks
Change
Date
9.51723 % Gomi (Daisuke)8,540,0002,040,0002/20/2025
6.25195 % JIC Venture Growth Investments Co., Ltd.5,610,00006/30/2024
5.86959 % Taiyo Pacific Partners LP5,266,900-959,6002/10/2025
4.29078 % Nomura Asset Management Co., Ltd.3,850,200263,0007/31/2024
2.70389 % Citigroup Global Markets Ltd.2,426,2542,426,2546/30/2024
2.60866 % Asset Management One Co., Ltd.2,340,800623,2005/31/2024
2.57924 % The Vanguard Group, Inc.2,314,40001/31/2025
2.50121 % Goldman Sachs International2,244,389-155,59412/15/2023
2.19618 % Capital Research Global Investors1,970,68002/15/2024
2.10085 % Pfizer Japan Inc.1,885,13606/30/2024
1
2
3
4
5
...
10

Nxera Pharma Co Executives and Management Board

Mr. Christopher Cargill

(40)
Nxera Pharma Co President, Representative Executive Officer, Chief Executive Officer, President of Subsidiary, Director (since 2018)
Compensation 312 M

Dr. Matthew Barnes

(50)
Nxera Pharma Co Executive Vice President, President of Subsidiary
Compensation 105 M

Mr. Kieran Johnson

(54)
Nxera Pharma Co Executive Vice President, Chief Accounting Officer
Compensation 104 M

Dr. Shinichi Tamura

(74)
Nxera Pharma Co Chairman of the Board (since 1990)

Mr. Hironoshin Nomura

(40)
Nxera Pharma Co Chief Financial Officer, Executive Vice President
1
2
3
4

Nxera Pharma Co Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Aukett Swanke Group Stock
Aukett Swanke Group
SupplierCustomer -0,250,500,530,400,24
Takeda Pharmaceutical Stock
Takeda Pharmaceutical
SupplierCustomer0,900,44-0,49-0,89-0,41-0,16
Biohaven Pharm Holding Stock
Biohaven Pharm Holding
SupplierCustomer0,88-0,72-0,27 0,210,12
Daiichi Sankyo Stock
Daiichi Sankyo
SupplierCustomer0,86-0,49-0,79-0,14-0,040,07
MorphoSys Stock
MorphoSys
SupplierCustomer0,820,860,900,950,49-0,03
AstraZeneca Stock
AstraZeneca
SupplierCustomer0,810,70-0,36-0,75-0,68-0,49
Neurocrine Biosciences Stock
Neurocrine Biosciences
SupplierCustomer0,750,580,76-0,410,120,07
Sanofi Stock
Sanofi
SupplierCustomer0,670,53-0,46-0,80-0,81-0,45
GlaxoSmithKline Stock
GlaxoSmithKline
SupplierCustomer0,640,67-0,54-0,50-0,61-0,42
rakumo Stock
rakumo
SupplierCustomer0,100,790,770,920,81
1
2

Most common questions regarding Nxera Pharma Co

What values and corporate philosophy does Nxera Pharma Co represent?

Sosei Group Corp represents values of innovation, collaboration, and global expansion. With a commitment to creating groundbreaking pharmaceuticals, the company focuses on leveraging their proprietary drug discovery platforms to develop novel treatments for unmet medical needs. Sosei Group Corp strives to foster partnerships with other industry leaders to enhance research and development capabilities and accelerate the delivery of life-changing therapeutics to patients worldwide. Emphasizing patient-centricity, Sosei Group Corp aims to improve healthcare and contribute to society through its cutting-edge technologies and commitment to scientific excellence.

In which countries and regions is Nxera Pharma Co primarily present?

Sosei Group Corp is primarily present in Japan and the United Kingdom.

What significant milestones has the company Nxera Pharma Co achieved?

Some significant milestones achieved by Sosei Group Corp include the successful completion of clinical trials for multiple novel therapeutic candidates, such as R-pasudotox, NVA237, and QVA149. The company also entered into strategic alliances and partnerships with major pharmaceutical companies, allowing for the development and commercialization of its products on a global scale. Furthermore, Sosei Group Corp successfully launched its first proprietary product, SOF-021, for chronic obstructive pulmonary disease (COPD) in Japan. These milestones demonstrate the company's commitment to innovation and market expansion, solidifying its position as a leading player in the biopharmaceutical industry.

What is the history and background of the company Nxera Pharma Co?

Sosei Group Corp. is a renowned pharmaceutical company with a rich history and profound background. Founded in 1990, Sosei Group Corp. is headquartered in Tokyo, Japan. The company focuses on discovering, developing, and commercializing innovative medicines for various therapeutic areas. Sosei Group Corp. has a strong track record of successfully bringing novel drugs to market, addressing significant medical needs worldwide. With a team of experienced researchers and development experts, the company emphasizes cutting-edge technologies and collaborations to drive its discoveries. Sosei Group Corp. is committed to improving patients' lives through its groundbreaking pharmaceutical solutions while continuously expanding its global presence.

Who are the main competitors of Nxera Pharma Co in the market?

The main competitors of Sosei Group Corp in the market include multinational pharmaceutical companies such as Roche Holding AG, Novartis AG, and Pfizer Inc. These companies are also engaged in the research, development, and commercialization of innovative drugs and therapies. However, Sosei Group Corp stands out in the market due to its unique focus on drug discovery and development, utilizing its proprietary platform technologies. As a global biopharmaceutical company, Sosei Group Corp strives to differentiate itself and expand its product portfolio in its pursuit of breakthrough treatments and therapies.

In which industries is Nxera Pharma Co primarily active?

Sosei Group Corp is primarily active in the pharmaceutical and biotechnology industries.

What is the business model of Nxera Pharma Co?

The business model of Sosei Group Corp. focuses on discovering, developing, and commercializing innovative medicines. Sosei Group Corp. operates through two primary business segments: “Discovery and Early Development” and “Late-stage Development and Commercialization”. The company collaborates with global partners to research and create novel drugs and therapies addressing unmet medical needs in various therapeutic areas, including respiratory, neurology, and oncology. Sosei Group Corp. aims to leverage its proprietary technologies and expertise in drug discovery and development to deliver life-changing treatments to patients worldwide.

What is the P/E ratio of Nxera Pharma Co 2025?

The Nxera Pharma Co P/E ratio is 113.35.

What is the P/S ratio of Nxera Pharma Co 2025?

The Nxera Pharma Co P/S ratio is 2.3.

What is the Quality Investing of Nxera Pharma Co?

The Quality Investing for Nxera Pharma Co is 4/10.

What is the revenue of Nxera Pharma Co 2025?

The expected Nxera Pharma Co revenue is 36.56 B JPY.

How high is the profit of Nxera Pharma Co 2025?

The expected Nxera Pharma Co profit is 741 M JPY.

What is the business model of Nxera Pharma Co

The Sosei Group Corp is an innovative Japanese biopharmaceutical company that focuses on the discovery and development of new drugs. The company's business model consists of three main divisions: Sosei Heptares, Sosei NCE, and Sosei CMC. Sosei Heptares is the leading platform for the discovery and development of drugs targeting G-protein-coupled receptors (GPCRs). These receptors are an important target for a variety of diseases. Sosei Heptares has a robust pipeline with multiple clinical candidates in various therapeutic areas such as immunology, metabolism, neurology, and oncology. Key products of Sosei Heptares include the recently approved drugs Seebri Breezhaler and Utibron Neohaler for the treatment of COPD (chronic obstructive pulmonary disease). Sosei NCE focuses on the discovery and development of new drugs with innovative mechanisms of action and high therapeutic efficacy. The company is currently developing drugs for the treatment of non-infectious diseases such as cancer, inflammation, and metabolic disorders. A key product of Sosei NCE is the clinical candidate Oligo-controlled release (OCR) for the treatment of type 2 diabetes. Sosei CMC is the company's center of excellence for the chemical manufacturing of drugs. Sosei CMC offers a wide range of services, including process development, scale-up, and GMP production of NCEs, biological drugs, and inhalation products. The company has extensive experience in manufacturing drugs for clinical trials and commercial production. The business model of Sosei Group Corp is based on an integrated platform technology strategy. The company leverages its extensive expertise in GPCR research to discover innovative drug candidates that are further developed by its NCE and CMC divisions. Sosei Group Corp has entered into a number of partnerships with leading pharmaceutical companies such as AstraZeneca, Novartis, and Pfizer to accelerate the development and commercialization of its products. The company also aims to have a strong presence in the Japanese market and collaborates closely with Japanese companies such as Takeda Pharmaceutical, Ono Pharmaceutical, and Astellas Pharma. In addition, Sosei Group Corp has built a global presence by establishing branches and subsidiaries in North America, Europe, and Asia. In summary, Sosei Group Corp develops and markets innovative drug candidates through its integrated platform technology strategy, aiming to improve healthcare worldwide. The various divisions focusing on drug discovery, development, and chemical manufacturing form the foundation of this business model.

What is the Nxera Pharma Co dividend?

Nxera Pharma Co pays a dividend of 0 JPY distributed over payouts per year.

How often does Nxera Pharma Co pay dividends?

The dividend cannot currently be calculated for Nxera Pharma Co or the company does not pay out a dividend.

What is the Nxera Pharma Co ISIN?

The ISIN of Nxera Pharma Co is JP3431300007.

What is the Nxera Pharma Co WKN?

The WKN of Nxera Pharma Co is A0B7EK.

What is the Nxera Pharma Co ticker?

The ticker of Nxera Pharma Co is 4565.T.

How much dividend does Nxera Pharma Co pay?

Over the past 12 months, Nxera Pharma Co paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Nxera Pharma Co is expected to pay a dividend of 0 JPY.

What is the dividend yield of Nxera Pharma Co?

The current dividend yield of Nxera Pharma Co is .

When does Nxera Pharma Co pay dividends?

Nxera Pharma Co pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Nxera Pharma Co?

Nxera Pharma Co paid dividends every year for the past 0 years.

What is the dividend of Nxera Pharma Co?

For the upcoming 12 months, dividends amounting to 0 JPY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Nxera Pharma Co located?

Nxera Pharma Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Nxera Pharma Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Nxera Pharma Co from 6/24/2015 amounting to 10 JPY, you needed to have the stock in your portfolio before the ex-date on 3/27/2015.

When did Nxera Pharma Co pay the last dividend?

The last dividend was paid out on 6/24/2015.

What was the dividend of Nxera Pharma Co in the year 2024?

In the year 2024, Nxera Pharma Co distributed 0 JPY as dividends.

In which currency does Nxera Pharma Co pay out the dividend?

The dividends of Nxera Pharma Co are distributed in JPY.

All fundamentals about Nxera Pharma Co

Our stock analysis for Nxera Pharma Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nxera Pharma Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.